

TYPE S9/MEDIUM, AB/1-15

9/AB/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0013760373 BIOSIS NO.: 200200353884

Preclinical cancer vaccine studies in mice using a HER-2 peptide immunogen combined with the saponin-based immune enhancer GPI-0100 and polysaccharides

AUTHOR: May Richard D (Reprint); Triozzi Pierre L; Aldrich Wayne A;

Reynolds Robert C; Pathak Ashish K; Marciani Dante J

AUTHOR ADDRESS: Cancer Therapeutics and Immunology, Southern Research

Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA**USA

JOURNAL: FASEB Journal 16 (4): pA333 March 20, 2002 2002

MEDIUM: print

CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists on Experimental Biology New Orleans, Louisiana, USA April 20-24, 2002; 20020420

ISSN: 0892-6638

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: HER-2 is over-expressed by many common malignancies and is an attractive target antigen for vaccine approaches. An oligopeptide immunogen targeting a B-cell epitope of the HER-2 extracellular domain plus a measles virus T-helper epitope to augment immunogenicity was constructed. This chimeric immunogen, MVF-HER-2 (628-647), elicits HER-2-specific antibody with antitumor activity in mice. Oligopeptides are relatively weak immunogens in humans. Thus, immune enhancers (adjuvants) are needed for oligopeptide immunogens. Preclinical studies were conducted in mice to examine the immune responses of MVF-HER-2 combined with GPI-0100, a water-soluble, semi-synthetic triterpenoid saponin immune enhancer. To possibly further enhance activity, GPI-0100 was combined with two polysaccharides and their chemically-modified derivatives. These polysaccharides, pectin and carboxy-beta-glucan, are both immunologically active. Various formulations were used to immunize mice (2 biweekly s.c. injections). Controls were vehicle only (PBS) and MVF-HER-2 only. Two weeks after the second immunization, sera were tested for the antibody response by ELISA and spleen cells were tested for their in vitro antigen-specific T cell proliferative responses. Significant antibody and lymphoproliferative responses were induced. The results indicate that MVF-HER-2 and GPI-0100 (with or without polysaccharides) will make an effective cancer vaccine in upcoming clinical trials.

9/AB/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0013086641 BIOSIS NO.: 200100258480

Intranasal immunization with Type 3 polysaccharide and QS-21 or QS-7 affords protection in mice challenged with S. pneumoniae by the respiratory route

AUTHOR: Jackson Raymond J (Reprint); Boyaka Prosper N (Reprint); van Ginkel

Frederik W (Reprint); Kensil Charlotte R; Mcghee Jerry R (Reprint)

AUTHOR ADDRESS: UAB Medical Center, 845 19th St. So., Birmingham, AL, 35294, USA**USA

JOURNAL: FASEB Journal 15 (5): pA1189 March 8, 2001 2001

MEDIUM: print

CONFERENCE/MEETING: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001; 20010331

ISSN: 0892-6638

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Polysaccharides (PS) possess characteristics of T-cell independent Type 2 antigens. These traits include inability to stimulate MHC class II dependent T-cell help, inability to stimulate Ab responses in neonates, and generally do not induce memory responses. QS-21 and QS-7 are highly purified saponin derivatives. Mice were intranasally immunized (5 μ l/nare) three times at weekly intervals with 20 μ g of Type 3 PS with or without 20 μ g QS-21 or QS-7 as adjuvant. Plasma and fecal extracts were obtained on days 7, 14 and 21. Saliva was collected on day 21. Mice were challenged 4-5 weeks following the last immunization and monitored daily for survival. Seven days following challenge plasma, fecal extracts, nasal and bronchial washes were obtained. Type 3 specific Ab responses were monitored by ELISA. Both Type 3 specific IgM and IgG were evident 7 days after immunization in groups PS with QS-21 or QS-7. No Ab responses were seen in the PS only groups. The day 21 IgG titers reached 1:256 and 1: 512 for the QS-21 and QS-7 groups respectively. The IgM antigen titers were also modest with the QS-21 group reaching 1:64 while the QS-7 group reached 1:256. No antigen specific IgA was detected. To ensure responses were Type 3 specific we performed a micro bicinchoninic acid protein assay. No significant protein contamination was found (< 0.2 μ g/60 μ g PS). Preliminary results with mice surviving the challenge suggest that Type 3 PS plasma titers were not elevated from those at day 21 and antigen specific S-IgA was not induced at mucosal respiratory surfaces. We are currently testing these plasma samples for their opsonizing ability in an effort to establish correlates of immunity.

9/AB/3 (Item 3 from file: 5)

DIALOG(R)File 5:BIOSIS Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0010780455 BIOSIS NO.: 199799414515

Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice

AUTHOR: Rioux Stephane; Dubreuil Daniel; Begin Caroline; Laferriere Craig; Martin Denis; Jacques Mario (Reprint)

AUTHOR ADDRESS: Departement de Pathologie et Microbiologie, Faculte de Medecine Veterinaire, Universite de Montreal, C.P. 5000, St. Hyacinthe, PQ J2S 7C6, Canada**Canada

JOURNAL: Comparative Immunology Microbiology and Infectious Diseases 20 (1): p63-74 1997 1997

ISSN: 0147-9571

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia. The major adhesin of A. pleuropneumoniae has previously been identified as a lipopolysaccharide (LPS), and more recently, we demonstrated that high molecular mass LPS were involved in A. pleuropneumoniae adherence to porcine respiratory tract cells. We

postulated that immunization with a LPS-based vaccine may confer a protective immunity. The high molecular mass O-polysaccharides obtained after acid hydrolysis and chromatographic separation were conjugated to bovine serum albumin (BSA) as a protein carrier. Groups of mice were injected twice with the following antigen preparations: whole-cell preparation, outer membrane preparation, O-polysaccharide-BSA conjugate, hydrolyzed LPS and pheno/water extracted LPS. A combination of different adjuvants was also used during these immunization procedures to induce a stronger immunological response to the polysaccharide antigen. Two weeks after the second injection, the mice were challenged intranasally with either homologous *A. pleuropneumoniae* serotype 1 strain or a serotype 5 strain. The highest survival rate, up to 80%, compared to the control groups ($P < 0.05$), was recorded when the mice were injected twice with 15 μ -g of carbohydrates of O-polysaccharide-BSA conjugate mixed with the saponin-derived adjuvant Quil A. Survival rates of between 60 and 70%, twice those observed in the control groups immunized with PBS, were recorded in mice injected with the O-polysaccharide-BSA conjugate mixed with other adjuvant preparations such as alhydrogel, peanut oil and Freund's incomplete adjuvant. However, the protection induced by the conjugate antigen preparation was serotype specific, because mice challenged with a serotype 5 strain were killed. Taken together, these results confirm the important role of *A. pleuropneumoniae* LPS in pathogenesis.

9/AB/4 (Item 4 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0009724570 BIOSIS NO.: 199598192403

Adjuvant activity of QS-21 for experimental *E. coli* 018 polysaccharide vaccines

AUTHOR: Coughlin Richard T (Reprint); Fattom Ali; Chu Chiayung; White Abbie C; Winston Scott

AUTHOR ADDRESS: Cambridge Biotech Corp., 365 Plantation St., Worcester, MA 01605, USA**USA

JOURNAL: Vaccine 13 (1): p17-21 1995 1995

ISSN: 0264-410X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Three types of experimental vaccines containing O-side-chain polysaccharide from the enterotoxigenic strain *Escherichia coli* 018 were evaluated. The immunogenicity of free O-polysaccharide (PS), a polysaccharide-diphtheria toxoid conjugate (PS-conj), and detoxified lipopolysaccharide (dLPS) was tested in female ICR mice, either alone or in combination with QS-21, a purified saponin adjuvant derived from the bark of the tree *Quillaja saponaria* Molina. Both the number of individual mice responding and the titres of O-polysaccharide specific antibodies in pools of sera were increased by the addition of QS-21. The immune response to both O-specific polysaccharide and carrier was primarily IgM and IgG1. The addition of QS-21 not only increased the level of IgG1, but also had a significant adjuvant effect on antigen-specific IgG2a, IgG2b and IgG3.

9/AB/5 (Item 1 from file: 73)

DIALOG(R) File 73: EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

12206964 EMBASE No: 2003318638

Lipid and carbohydrate based adjuvant/carriers in immunology

McGeary R.P.; Olive C.; Toth I.

I. Toth, School of Molec./Microbial Sciences, School of Pharmacy, The University of Queensland, Brisbane, QLD 4072 Australia

AUTHOR EMAIL: i.toth@pharmacy.uq.edu.au

Journal of Peptide Science (J. PEPT. SCI.) (United Kingdom) 01 JUL 2003, 9/7 (405-418)

CODEN: JPSIE ISSN: 1075-2617

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 96

This review discusses various issues regarding vaccines; what are they and how they work, safety aspects, the role of adjuvants and carriers in vaccination, synthetic peptides as immunogens, and new technologies for vaccine development and delivery including the identification of novel adjuvants for mucosal vaccine delivery. There has been a recent increase of interest in the use of lipids and carbohydrates as adjuvants, and so a particular emphasis is placed on adjuvants derived from lipids or carbohydrates, or from both. Copyright (c) 2003 European Peptide Society and John Wiley & Sons, Ltd.

9/AB/6 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

12007968 EMBASE No: 2003118460

Astragalus membranaceus

Alternative Medicine Review (ALTERN. MED. REV.) (United States) 2003, 8/1 (72-77)

CODEN: ALMRF ISSN: 1089-5159

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 34

9/AB/7 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

06298443 EMBASE No: 1995321063

Adjuvants for human vaccines. Current status, problems and future prospects

Gupta R.K.; Siber G.R.

MA Public Health Biologic Labs., State Laboratory Institute, Boston, MA 02130 United States

Vaccine (VACCINE) (United Kingdom) 1995, 13/14 (1263-1276)

CODEN: VACCD ISSN: 0264-410X

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Adjuvants help antigen to elicit an early, high and long-lasting immune response with less antigen, thus saving on vaccine production, costs. In recent years, adjuvants received much attention because of the development of purified, subunit and synthetic vaccines which are poor immunogens and require adjuvants to evoke the immune response. With the use of adjuvants immune response can be selectively modulated to major histocompatibility

complex (MHC) class I or MHC class II and Th1 or Th2 type, which is very important for protection against diseases caused by intracellular pathogens such as viruses, parasites and bacteria (Mycobacterium). A number of problems are encountered in the development and use of adjuvants for human vaccines. The biggest issue with the use of adjuvants for human vaccines, particularly routine childhood vaccines is the toxicity and adverse side-effects of most of the adjuvant formulations. At present the choice of adjuvants for human vaccination reflects a compromise between a requirement for adjuvant activity and an acceptable low level of side-effects. Other problems with the development of adjuvants include restricted adjuvant activity of certain formulations to a few antigens, use of aluminum adjuvants as reference adjuvant preparations under suboptimal conditions, non-availability of reliable animal models, use of non-standard assays and biological differences between animal models and humans leading to the failure of promising formulations to show adjuvant activity in clinical trials. The most common adjuvants for human use today are still aluminum hydroxide and aluminum phosphate, although calcium phosphate and oil emulsions also have some use in human vaccinations. During the last 15 years much progress has been made on development, isolation and chemical synthesis of alternative adjuvants such as derivatives of muramyl dipeptide, monophosphoryl lipid A, liposomes, QS21, MF-59 and immunostimulating complexes (ISCOMS). Other areas in adjuvant research which have received much attention are the controlled release of vaccine antigens using biodegradable polymer microspheres and reciprocal enhanced immunogenicity of protein-polysaccharide conjugates. Biodegradable polymer microspheres are being evaluated for targeting antigens on mucosal surfaces and for controlled release of vaccines with an aim to reduce the number of doses required for primary immunization. Reciprocal enhanced immunogenicity of protein-polysaccharide conjugates will be useful for the development of combination vaccines.

9/AB/8 (Item 4 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

05660505 EMBASE No: 1994076726

**Effect of adjuvants on immunogenicity of a Salmonella typhi
O-polysaccharide-tetanus toxoid conjugate**

Saxena M.; Di Fabio J.L.

DRC RDV, Pan American Health Organization, 525 Twenty-Third
Street, Washington DC 20037 United States

Vaccine Research (VACCINE RES.) (United States) 1993, 2/3 (207-214)

CODEN: VAREE ISSN: 1056-7909

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The effect of Quil A and Alhydrogel on enhancing mouse immunogenicity of a Salmonella typhi O-chain-tetanus toxoid-conjugated vaccine was compared to Freund's adjuvant. Animals were injected with 5 mug of conjugate with respective adjuvant, boosted 3 weeks later, and sera examined for development of anti-polysaccharide and anti-protein antibodies. Highest anti-polysaccharide antibody titers were seen with Freund's, followed by Quil A and Alhydrogel. Maximum anti-tetanus antibodies were seen with Quil A, followed by Freund's. Isotype analysis of anti-polysaccharide antibodies showed the predominance of IgGinf 1 antibodies with all three adjuvants. The bactericidal activity toward S.typhi of sera was measured in vitro and bactericidal titers were found to be 220, 110, and <20 for Freund's, Quil A, and Alhydrogel, respectively. The results show the saponin adjuvant Quil A to be a good substitute for Freund's in the preclinical evaluation of new

polysaccharide-protein conjugated vaccines.

9/AB/9 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

09251552 PMID: 1805566

A purified saponin acts as an adjuvant for a T-independent antigen.

White A C; Cloutier P; Coughlin R T

Cambridge Biotech Corporation, Worcester, MA 01605.

Advances in experimental medicine and biology (UNITED STATES) 1991,
303 p207-10, ISSN 0065-2598 Journal Code: 0121103

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Three strains of mice were injected with a T-independent antigen, Escherichia coli 055:B5 polysaccharide (PS) combined with purified saponin, QS-21, isolated from Quillaja saponaria bank. PS was prepared by hydrolysis of lipopolysaccharide (LPS). Nine week old mice were injected intradermally with 60 micrograms PS, as determined by an anthrone assay, with or without 15 micrograms QS-21 on days 0 and 14. On day 22 sera were assayed by EIA for PS specific antibodies. Titers were 11-fold higher in CD-1 mice with QS-21. C3H/HeJ (Ipsd) and C3H/HeSnJ (Ipsr) mice also showed an adjuvant associated increase in titer with saponin. Therefore, LPS responsiveness was not required for the adjuvant effect. PS vaccinated C3H and CD-1 mice with and without QS-21 had similar antibody isotype profiles. IgG2b titers accounted for more than half of the total Ig response. IgG2a was next highest followed by IgG3, IgM, IgG1, and IgA. In comparison, CD-1 mice injected with 0.1 microgram intact LPS had a different LPS specific isotype profile. IgG3 was the highest followed by IgG1, IgG2b, IgM, IgG2a, and IgA.

9/AB/10 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

141156099 CA: 141(10)156099e PATENT

Polyvalent antigen conjugates as vaccines against prostate, lung, breast and ovarian cancer

INVENTOR(AUTHOR): Livingston, Philip O.; Ragupathi, Govindaswami;
Danishefsky, Samuel J.

LOCATION: USA

ASSIGNEE: Sloan-Kettering Institute for Cancer Research

PATENT: U.S. Pat. Appl. Publ. ; US 20040151733 A1 DATE: 20040805

APPLICATION: US 752945 (20040106) *US PV303494 (20010706) *US PV347231
(20020110) *WO 2002US21348 (20020705)

PAGES: 56 pp., Cont.-in-part of WO 2003 3,985. CODEN: USXXCO LANGUAGE:
English CLASS: 424185100; A61K-031/739A; A61K-039/00B

9/AB/11 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

138302637 CA: 138(20)302637k PATENT

Intradermal vaccine compositions comprising saponin, sterol, and LPS derivative or CpG oligonucleotide as adjuvant

INVENTOR(AUTHOR): Garcon, Nathalie

LOCATION: Belg.
ASSIGNEE: Glaxosmithkline Biologicals S.A.
PATENT: PCT International ; WO 200328760 A2 DATE: 20030410
APPLICATION: WO 2002EP10931 (20020930) *GB 200123580 (20011001)
PAGES: 27 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/39A;
A61K-009/127B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG
; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI;
GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK;
LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT;
RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN;
YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH
; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ;
DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ;
CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

9/AB/12 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2005 American Chemical Society. All rts. reserv.

136339479 CA: 136(22)339479v PATENT
Vaccines comprise cancer antigen and saponin and immunostimulatory oligonucleotide
INVENTOR(AUTHOR): Garcon, Nathalie; Gerard, Catherine Marie Ghislaine;
Stephennne, Jean
LOCATION: Belg.
ASSIGNEE: Smithkline Beecham Biologicals SA
PATENT: PCT International ; WO 200232450 A2 DATE: 20020425
APPLICATION: WO 2001EP11984 (20011016) *GB 200025573 (20001018) *GB
200025574 (20001018) *US 690921 (20001018)
PAGES: 49 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SD; SE; SG;
SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY;
KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL
; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;
MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN;
TD; TG

9/AB/13 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2005 American Chemical Society. All rts. reserv.

134004039 CA: 134(1)4039c PATENT
Adjuvant combinations for immunization composition and vaccines
INVENTOR(AUTHOR): Lindblad, Erik B.; Elhay, Martin J.; Andersen, Peter;
Brandt, Lise Ostergaard
LOCATION: Den.
ASSIGNEE: Statens Serum Institut
PATENT: PCT International ; WO 200069458 A2 DATE: 20001123
APPLICATION: WO 2000DK251 (20000512) *DK 99655 (19990512)
PAGES: 26 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/39A
DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH;
CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL;
IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK;
MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT;
TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

9/AB/14 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

133115532 CA: 133(9)115532g PATENT

Improved saponin adjuvant compositions and methods relating thereto

INVENTOR(AUTHOR): Walker, John

LOCATION: Australia

ASSIGNEE: CSL Limited

PATENT: PCT International ; WO 200041720 A1 DATE: 20000720

APPLICATION: WO 99AU1167 (19991224) *AU 998073 (19990108)

PAGES: 53 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/39A

DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

9/AB/15 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.

132193246 CA: 132(15)193246k PATENT

Compositions of CpG and saponin adjuvants and methods thereof

INVENTOR(AUTHOR): Kensil, Charlotte A.

LOCATION: USA

ASSIGNEE: Aquila Biopharmaceuticals, Inc.

PATENT: PCT International ; WO 200009159 A1 DATE: 20000224

APPLICATION: WO 99US17956 (19990806) *US 95913 (19980810) *US 128608 (19990408)

PAGES: 38 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/39A; C07H-015/24B; C07J-017/00B; C07H-021/00B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

?

Set	Items	Description
S1	13975	IMMUNOGEN
S2	164134	ADJUVANT
S3	176691	S1 OR S2
S4	0	S4 AND SAPONIN
S5	901	S3 AND SAPONIN
S6	17882	5 AND DEXTRAN

S7	7	S5 AND DEXTRAN
S8	19	S5 AND POLYSACCHARIDE
S9	15	RD S8 (unique items)
?		

Day : Tuesday
Date: 2/15/2005


PALM INTRANET

Time: 19:08:19

Inventor Name Search Result

Your Search was:

Last Name = WALKER

First Name = JOHN

Application#	Patent#	Status	Date Filed	Title	Inventor Name 51
60622941	Not Issued	020	10/28/2004	NOVEL PHARMACEUTICALS	WALKER, JOHN K.
60494959	Not Issued	159	08/13/2003	SUBSTITUTED PYRIDINONES	WALKER, JOHN
60488378	Not Issued	159	07/18/2003	SUBSTITUTED PYRIDAZINONES	WALKER, JOHN
60386415	Not Issued	159	06/05/2002	NOVEL PYRAZOLES AND THEIR USE AS P38 KINASE INHIBITORS	WALKER, JOHN K.
60357807	Not Issued	159	10/26/2001	USING ARTIFICIAL PAGES IN VISUAL JOB TICKETING	WALKER, JOHN STUART
60357806	Not Issued	159	10/26/2001	VISUAL JOB TICKETING USING A DOCUMENT VIEWING APPLICATION	WALKER, JOHN STUART
60357029	Not Issued	159	02/14/2002	DIARYL SUBSTITUTED PYRIDINONES	WALKER, JOHN
60355044	Not Issued	159	02/07/2002	DIARYL SUBSTITUTED PYRIDAZINONES	WALKER, JOHN
60350741	Not Issued	159	01/18/2002	DIARYL SUBSTITUTED PYRIDAZINONES	WALKER, JOHN
60349028	Not Issued	159	01/15/2002	METHOD FOR USING A MOTORIZED CAMERA MOUNT FOR TRACKING IN AUGMENTED REALITY	WALKER, JOHN F.
60217763	Not Issued	159	07/12/2000	METHOD, APPARATUS AND SYSTEM FOR FINGERPRINT AUTHENTICATION AND CONTROLLING INFORMATION BASED ON THE FINGERPRINT AUTHENTICATION	WALKER, JOHN
60212819	Not Issued	159	06/21/2000	CARBON TETRACHLORIDE IN VEGETATION AND ITS	WALKER, JOHN L.

				APPLICATION TO EXPEDITED SITE CHARACTERIZATION	
<u>60208113</u>	Not Issued	159	05/31/2000	METHOD, APPARATUS & SYSTEM FOR ELECTRONIC ADVERTISING AND INFORMATION MANAGEMENT OVER THE INTERNET	WALKER, JOHN TROY
<u>60206411</u>	Not Issued	159	05/23/2000	FOUNTAIN	WALKER, JOHN M.
<u>29187377</u>	<u>D490442</u>	150	07/31/2003	SUBMERSIBLE PUMP	WALKER, JOHN M.
<u>10977850</u>	Not Issued	020	10/29/2004	METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR DETECTING MUSICAL NOTES IN AN AUDIO SIGNAL	WALKER, JOHN Q.
<u>10470357</u>	Not Issued	061	07/25/2003	METHOD OF SELECTING WOOD FOR MECHANICAL PULPING	WALKER, JOHN CORRIE FLEMING
<u>10465662</u>	Not Issued	041	06/20/2003	SHELL-MOLDED FAT- CONTAINING CONFECTIONERY PRODUCTS WITH VISCOUS FILLING	WALKER, JOHN HOWARD
<u>10456933</u>	Not Issued	030	06/05/2003	NOVEL PYRAZOLES AND THEIR USE AS P38 KINASE INHIBITORS	WALKER, JOHN K.
<u>10447090</u>	Not Issued	041	05/28/2003	DRIVE APPARATUS	WALKER, JOHN L.
<u>10430619</u>	Not Issued	030	05/06/2003	SECURE PRINT CONTROL AND RIGHTS MANAGEMENT SYSTEM	WALKER, JOHN STUART
<u>10410336</u>	Not Issued	030	04/09/2003	USER SELECTOR PROXY, METHOD AND SYSTEM FOR AUTHENTICATION, AUTHORIZATION AND ACCOUNTING	WALKER, JOHN MICHAEL
<u>10409499</u>	<u>6822282</u>	150	04/08/2003	ANALOG CAPACITOR IN DUAL DAMASCENE PROCESS	WALKER, JOHN DE Q.
<u>10406150</u>	Not Issued	041	04/01/2003	PROCESS FOR MAKING SUBSTITUTED PYRAZOLES	WALKER, JOHN K.
<u>10367987</u>	Not Issued	041	02/14/2003	SUBSTITUTED PYRIDINONES	WALKER, JOHN
<u>10347853</u>	Not	041	01/21/2003	SUBSTITUTED	WALKER, JOHN

	Issued			PYRIDAZINONES	
<u>10192195</u>	Not Issued	092	07/10/2002	METHOD TO VIEW UNSEEN ATMOSPHERIC PHENOMENON USING AUGMENTED REALITY	WALKER, JOHN FRANKLIN
<u>10123364</u>	<u>6822648</u>	150	04/16/2002	METHOD FOR OCCLUSION OF MOVABLE OBJECTS AND PEOPLE IN AUGMENTED REALITY SCENES	WALKER, JOHN FRANKLIN
<u>10123315</u>	Not Issued	094	04/16/2002	METHOD TO AUGMENT IMAGERY TO DISPLAY 3-D PROBABILISTIC OBJECT LOCATIONS	WALKER, JOHN FRANKLIN
<u>10081357</u>	Not Issued	061	02/22/2002	SCREEN CLOTH INSERTION APPARATUS AND METHOD	WALKER, JOHN A.
<u>10019087</u>	Not Issued	061	12/19/2001	METHOD FOR DETECTING A LIPOPROTEIN-ACUTE PHASE PROTEIN COMPLEX AND PREDICTING AN INCREASED RISK OF SYSTEM FAILURE OR MORTALITY	WALKER, JOHN B
<u>09890650</u>	<u>6685947</u>	150	03/22/2002	T HELPER CELL EPITOPES	WALKER, JOHN
<u>09756569</u>	Not Issued	164	01/08/2001	OPTICAL CHANNELIZER AND ROUTER AND ROUTING METHOD	WALKER, JOHN
<u>09732168</u>	<u>6554818</u>	150	12/07/2000	METHOD OF FILLING A DRUG CAPSULE AND ARTICLE PRODUCED THEREBY	WALKER, JOHN NICHOLAS
<u>09680564</u>	Not Issued	041	10/05/2000	DESIGN OF DIGITAL VIDEO RECORDER/PLAYER	WALKER, JOHN
<u>09678254</u>	Not Issued	160	10/03/2000	INJECTION MOLDING OF THERMOPLASTIC PARTS	WALKER, JOHN D.
<u>09677887</u>	Not Issued	160	10/03/2000	INJECTION MOLDING OF THERMOPLASTIC PARTS WITH REDUCED SPRUE	WALKER, JOHN D.
<u>09634203</u>	Not Issued	161	08/09/2000	AUGMENTED REALITY NAVIGATION AID	WALKER, JOHN F.
<u>09632957</u>	<u>6630339</u>	150	08/04/2000	GLYCINE AND PHASEOLUS ALPHA-D-GALACTOSIDASES	WALKER, JOHN C.
<u>09606140</u>	<u>PP12656</u>	150	06/28/2000	BEGONIA PLANT NAMED 'DOUBLET PINK'	WALKER, JOHN TREVOR
<u>09606139</u>	<u>PP12674</u>	150	06/28/2000	BEGONIA PLANT NAMED 'DOUBLET WHITE'	WALKER, JOHN TREVOR
<u>09606138</u>	<u>PP12644</u>	150	06/28/2000	BEGONIA PLANT NAMED	WALKER, JOHN

				'DOUBLET ROSE'	TREVOR
09606121	PP12638	150	06/28/2000	BEGONIA PLANT NAMED 'DOUBLET RED'	WALKER, JOHN TREVOR
09591642	Not Issued	168	06/09/2000	METHOD FOR DETECTING A LIPOPROTEIN-ACUTE PHASE PROTEIN COMPLEX AND PREDICTING AN INCREASED RISK OF SYSTEM FAILURE OR MORTALITY	WALKER, JOHN B.
09578054	Not Issued	161	05/24/2000	COMPUTER IMPLEMENTED SYSTEM AND METHOD FOR ASSESSING THE INTELLECTUAL PROPERTY ASSETS OF AN ENTITY	WALKER, JOHN A.
09562875	Not Issued	164	05/01/2000	INJECTION MOLDING OF THERMOPLASTIC PARTS	WALKER, JOHN D.
09559934	6342734	150	04/27/2000	INTERCONNECT- INTEGRATED METAL- INSULATOR-METAL CAPACITOR AND METHOD OF FABRICATING SAME	WALKER, JOHN Q.
09558917	Not Issued	161	04/26/2000	METHOD AND APPARATUS FOR MANUFACTURING SELF- SEALING DETACHABLE BALLOON AND VALVE	WALKER, JOHN D.
09511647	Not Issued	161	02/22/2000	HIGH DOSE P+ BURIED LAYER STRUCTURE FOR LATCHUP PROTECTION AND INTRINSIC MOBILE ION GATHERING	WALKER, JOHN D.
09464152	6498020	150	12/27/1999	FUSION PROTEINS COMRISING COILED-COIL STRUCTURES DERIVED OF BOVINE IF1 ATPASE INHIBITOR PROTEIN	WALKER, JOHN
09442124	Not Issued	161	02/11/1999	FUSION PROTEINS COMPRISING COILED-COIL STRUCTURES	WALKER, JOHN

[Search and Display More Records.](#)

Search Another: Inventor
Last Name
First Name
Search

walker
john

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)